Your session is about to expire
← Back to Search
GSK3882347 for Urinary Tract Infection (UTI)
Study Summary
This trial is testing a new drug, GSK3882347, to see if it is effective and safe for treating urinary tract infections in women. The trial is double-blind, meaning neither the participants nor the researchers will know who is receiving the new drug and who is receiving the standard treatment drug, nitrofurantoin, until the trial is over. The trial is also double-dummy, meaning that both the new drug and the standard treatment will be given in a way that neither the participants nor the researchers will know which is which. The trial will be conducted in two cohorts: inpatient and outpatient. During the inpatient period
- Urinary Tract Infection (UTI)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 trial • 61 Patients • NCT04488770Trial Design
Find a Location
Logistics
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are there other studies which have examined the impact of GSK3882347 on patients?
"Currently, 7 trials are in progress regarding GSK3882347 with 1 trial at Phase 3. Several of these clinical experiments occur around Cornellà De Llobregat, Catalonia whereas 33 other locations conduct research about this medication."
What is the scope of this research project in regards to location within the state?
"Currently, 5 locations are enrolling participants in this clinical trial. These sites can be found in Austin, Anniston, La Mesa and a couple of other places. To avoid excessive travel costs it is advisable to select the closest centre possible if you decide to partake."
Is enrollment open to individuals younger than 75 years of age for this medical research?
"According to the enrollment guidelines of this trial, individuals between 18 and 70 may be considered for inclusion. Notably, there are 205 clinical trials designed for those younger than 18 years old and 628 studies available for seniors aged 65 or older."
Is GSK3882347 a risk to patient safety?
"With limited clinical data to support safety and efficacy, GSK3882347 was rated a 1 on our team's scale."
Approximately how many individuals are engaged in this research?
"Affirmative. As evidenced on clinicaltrials.gov, this medical research is still recruiting volunteers for its trial which was first uploaded on May 18th 2022 and last updated November 11th 2022. The project needs 80 participants from 5 different locations in total."
Is this trial still open and accepting participants?
"The details on clinicaltrials.gov reveals that this trial is currently welcoming participants, with the initial posting taking place on May 18th 2022 and most recent update occurring November 11th of the same year."
Who is eligible to apply for participation in this clinical study?
"The requirements for this trial state that participants must be aged between 18 and 70, with a communicable illness. 80 individuals are being sought to contribute to the research."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- GSK Investigational Site: < 48 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger